Can Geriatricians Prescribe Cannabis for Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As the use of medical cannabis continues to grow in the UK, some families and clinicians wonder whether geriatricians can prescribe cannabis for dementia-related symptoms. While geriatricians are key in managing older adults’ health, the short answer is that dementia is not currently a qualifying condition for medical cannabis under UK law.

The Legal Framework for Cannabis Prescription

Under the Misuse of Drugs Regulations 2001, cannabis-based medicinal products (CBPMs) are classified as Schedule 2 controlled drugs. This means they can only be prescribed by specialist doctors who are registered with the General Medical Council (GMC) and are on the specialist register.

While geriatricians are specialists in older adult care, dementia does not currently qualify for cannabis treatment in the UK. According to NICE guidance (NG97), cannabis is not recommended for managing cognitive symptoms or behavioural challenges in dementia.

Can Geriatricians Prescribe Cannabis?

Geriatricians, as specialists in caring for elderly patients, can prescribe cannabis-based products if they are on the GMC Specialist Register and the treatment is for an approved condition such as chronic pain or spasticity due to multiple sclerosis. However, as dementia is not a licensed indication for CBPMs, geriatricians cannot prescribe cannabis for dementia symptoms, unless it is part of an off-label prescription after clinical justification, and with clear documentation of the patient’s condition and risks involved.

Under NICE guidelines, geriatricians can consider the use of cannabis-based products only when other conventional treatments have failed and with appropriate ongoing monitoring. This could theoretically apply in specific cases, such as when cannabis is prescribed for a comorbid condition like chronic pain, but not directly for dementia.

Ethical and Clinical Oversight

For cannabis use to be considered in dementia care, geriatricians must follow strict ethical protocols, including ensuring informed consent or using best-interest decisions under the Mental Capacity Act 2005 (UK legislation) when the patient lacks capacity. The CQC also mandates that any prescription of CBPMs, including in nursing homes or care facilities, is thoroughly recorded and reviewed to meet regulatory standards for controlled drugs (CQC, 2024).

Clinical Bottom Line

Geriatricians can prescribe cannabis only if the treatment is for an approved medical condition under specialist care.

Dementia is not an approved indication for medical cannabis in the UK.

Any off-label use must be clinically justified, thoroughly documented, and involve ongoing patient monitoring.

Informed consent and multidisciplinary oversight are essential.

Educational Context: AlleviMed

AlleviMed provides educational resources about the legal and clinical frameworks for cannabis use in the UK. It explains the processes for prescribing controlled drugs and helps healthcare professionals stay updated on regulations.

Takeaway

Geriatricians cannot prescribe cannabis for dementia symptoms in the UK, as dementia is not a licensed condition for CBPMs. If considering off-label use, geriatricians must carefully document and monitor treatment within multidisciplinary teams to ensure patient safety and compliance with NHS regulations.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.